HYDERABAD, India, November 9, 2017 /PRNewswire/ --
Granules India Ltd., a growing pharmaceutical manufacturing company, announced today financial results for its second quarter ended 30th September, 2017.
Quarterly Financial Highlights of Q2FY18 Consolidated Margins (%) Revenue: INR 393 Cr. - EBITDA: INR 84 Cr. 21.3% Net Profit: INR 40 Cr. 10.3%
The Company's standalone sales during the quarter were INR 374 Cr. In this quarter, the Company recorded EBITDA and PAT of INR 84 Cr. and INR 36 Cr., respectively.
The Company's Board of Directors has approved second interim dividend of 25 paise per share of face value of Rs. 1 each.
"We are pleased to report a moderate top-line growth for the current quarter compared with same quarter of the previous financial year. This comes at the backdrop of increased sales from formulation business and higher revenue generated from the North American market. As our emerging business is taking shape to drive future business growth, our core business continues to deliver sustainable revenues. During the quarter, we raised INR 300 Cr. through Qualified Institutional Placements (QIP). This not only validates the trust of our shareholders in the future prospects of the company but also helped us to fund our expansion plans," said Mr. Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India.
About Granules India Ltd. (BSE: 532482, NSE: GRANULES)
Granules India is a growing pharmaceutical manufacturing company with best in class facilities and is committed to operational excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) which gives the customers flexibility and choice. Granules support customers with unique value, extensive product range, and proactive solutions. The Company's global presence extends to over 250 customers in 60 countries through offices in India, U.S., and U.K. For more details, please visit: http://www.granulesindia.com/ .